The Role of a Clinical Pharmacist in Lifestyle Modification in Type 2 Diabetic Patients With Peripheral Neuropathy

Study Overview
=================
Brief Summary
-----------------
The aims of this study are to determine the prevalence of diabetic peripheral neuropathy among the diabetic patients, to determine the association between the clinical profiles of the diabetic patients (diabetes type, diabetes duration, HbA1c, body mass index, hypertension, total cholesterol) and the diabetic peripheral neuropathy DPN and the rational poly pharmacy used to control pain.

Official Title
-----------------
The Role of a Clinical Pharmacist in Lifestyle Modification

Conditions
-----------------
Diabetic Peripheral Neuropathy

Intervention / Treatment
-----------------
* Other: Diabetic patients with neuropathy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Aged 18 years or older. Both sex. Diagnosed with type 2 diabetes at least one year previously. Took at least one prescribed medication for diabetes. Diagnosed as diabetic peripheral neuropathy based on clinical Exclusion Criteria: History of alcohol consumption. Thyroid gland disorder. Any kidney disorder. Any conditions that could confound assessment of pain due to diabetic peripheral neuropathy. Have foot injury or open sore. Pregnant females or who plan to become pregnant during the study period. Any serious medical condition that might prevent completion or hinder compliance with exercise. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention Group<br>The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist. | Other: Diabetic patients with neuropathy<br>* Lifestyle modification will be assessed using summary of diabetes self-care activity<br>* Other names: Intervention group;|
| No Intervention: Usual care Group<br>The usual care group will be provided the standard medical services | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimating Summary of diabetes self-care activity (SDSCA) | Assessing Lifestyle modification by summary of diabetes self-care activity (SDSCA) at baseline visit and after three months for both Intervention patients and usual care group Increases in the means of the items of the scale as Exercise, Blood sugar testing, Specific diet and Foot care in the intervention group. | Three months | 
| Adherence to treatment according to Morisky scale | Morisky scale is used to assess medication adherence at baseline visit and after three months for both Intervention patients and usual care group. Improving the patient medication adherence behavior in the intervention group patients | Three months | 
| Douleur Neuropathique 4 (DN4), Neuropathic Pain Scale (NPS), | Reduction in the percent of response of patients feeling; electric shock, tingling, and pin needle after the lifestyle modification in the intervention group. | Three months |